全球皮下给药装置市场规模、份额、趋势和成长分析报告（2026-2034）

预计到 2034 年，皮下药物输送装置市场规模将达到 837.3 亿美元，高于 2025 年的 416.4 亿美元，预计从 2026 年到 2034 年的复合年增长率将达到 8.07%。

随着医疗专业人员越来越多地采用更便利、更人性化的治疗方法，全球皮下给药装置市场正显着成长。这些装置将药物输送到皮下，使其缓慢吸收进入血液。它们广泛应用于糖尿病、自体免疫疾病和荷尔蒙失调等慢性疾病的治疗。患者对自我给药疗法的日益偏好是推动市场扩张的主要因素。

市场成长主要受需要长期服药的慢性病盛行率上升的推动。病人和医护人员更倾向于使用皮下给药装置，因为它们可以减少频繁就医的次数，简化治疗流程。医疗设备技术的进步提高了这些装置的精准度、安全性和易用性，使其更适合居家照护。

随着製药公司不断研发需要专用给药系统的生物製药，皮下给药装置市场仍前景广阔。穿戴式註射器和智慧给药装置的创新有望进一步提高患者的治疗依从性。医疗保健服务的普及和居家医疗解决方案的日益普及预计将推动市场持续成长。

目录

第一章：引言

第2章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球皮下给药装置市场：依产品类型划分

• 市场分析、洞察与预测
• 预填充式注射器
• 自动喷油器
• 穿戴式註射器
• 其他的

第五章 全球皮下给药装置市场：依应用领域划分

• 市场分析、洞察与预测
• 糖尿病
• 肿瘤学
• 自体免疫疾病
• 其他的

第六章 全球皮下给药装置市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 诊所
• 居家医疗环境
• 其他的

第七章 全球皮下给药装置市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球皮下给药装置市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Johnson & Johnson
  • Sanofi SA
  • Pfizer Inc
  • Abbott Laboratories
  • GlaxoSmithKline Plc
  • Bayer AG
  • Novartis AG
  • Merck & Co. Inc
  • F. Hoffmann-La Roche Ltd
  • Novo Nordisk A/S
  • Medtronic Plc
  • Becton
  • Dickinson And Company（BD）
  • Insulet Corporation
  • AstraZeneca Plc
  • Amgen Inc

The Subcutaneous Drug Delivery Devices Market size is expected to reach USD 83.73 Billion in 2034 from USD 41.64 Billion (2025) growing at a CAGR of 8.07% during 2026-2034.

The global subcutaneous drug delivery devices market has grown significantly as healthcare providers increasingly adopt convenient and patient-friendly treatment methods. These devices deliver medications beneath the skin, allowing drugs to be absorbed slowly into the bloodstream. They are widely used for managing chronic conditions such as diabetes, autoimmune diseases, and hormonal disorders. The increasing preference for self-administration therapies has supported the expansion of this market.

Market growth is driven by the rising prevalence of chronic diseases that require long-term medication. Patients and healthcare providers favor subcutaneous delivery devices because they reduce the need for frequent hospital visits and simplify treatment routines. Advances in medical device technology have also improved device accuracy, safety, and ease of use, making them suitable for home-based care.

The future outlook for the subcutaneous drug delivery devices market remains promising as pharmaceutical companies continue to develop biologic drugs that require specialized delivery systems. Innovations in wearable injectors and smart drug delivery devices may further improve patient adherence to treatment. Expanding healthcare access and increasing adoption of home healthcare solutions are expected to drive continued market growth.

MARKET SEGMENTATION

By Product Type

• Prefilled Syringes
• Autoinjectors
• Wearable Injectors
• Others

By Application

• Diabetes
• Oncology
• Autoimmune Diseases
• Others

By End-User

• Hospitals
• Clinics
• Home Care Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Johnson Johnson, Sanofi SA, Pfizer Inc, Abbott Laboratories, GlaxoSmithKline plc, Bayer AG, Novartis AG, Merck Co Inc, F HoffmannLa Roche Ltd, Novo Nordisk AS, Medtronic plc, Becton, Dickinson and Company BD, Insulet Corporation, AstraZeneca plc, Amgen Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Prefilled Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Autoinjectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Wearable Injectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Home Care Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product Type
  • 8.2.2 By Application
  • 8.2.3 By End-user
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product Type
  • 8.3.2 By Application
  • 8.3.3 By End-user
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product Type
  • 8.4.2 By Application
  • 8.4.3 By End-user
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product Type
  • 8.5.2 By Application
  • 8.5.3 By End-user
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product Type
  • 8.6.2 By Application
  • 8.6.3 By End-user
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Johnson & Johnson
  • 10.2.2 Sanofi S.A
  • 10.2.3 Pfizer Inc
  • 10.2.4 Abbott Laboratories
  • 10.2.5 GlaxoSmithKline Plc
  • 10.2.6 Bayer AG
  • 10.2.7 Novartis AG
  • 10.2.8 Merck & Co. Inc
  • 10.2.9 F. Hoffmann-La Roche Ltd
  • 10.2.10 Novo Nordisk A/S
  • 10.2.11 Medtronic Plc
  • 10.2.12 Becton
  • 10.2.13 Dickinson And Company (BD)
  • 10.2.14 Insulet Corporation
  • 10.2.15 AstraZeneca Plc
  • 10.2.16 Amgen Inc